ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1239

Peripheral Protein Biomarker Changes Following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Methotrexate Naïve Adults with Moderately-to-Severely Active Rheumatoid Arthritis
Abstract Number: 1240

An Increase in Red Cell Mean Corpuscular Volume by Methotrexate Is Potentiated by Hydroxychloroquine and Predicts Clinical Response in Rheumatoid Arthritis
Abstract Number: 1241

Patient-Reported Outcomes in Rheumatoid Arthritis Patients Treated with Tofacitinib or Biological DMARDs in Real Life Conditions in Two Latin America Countries
Abstract Number: 1242

Transcranial Direct Current Stimulation for Fatigue in Patients with Sjogren’s Syndrome: A Randomized, Double-blind Pilot Study
Abstract Number: 1243

Self-reported Fatigue in Patients with Primary Sjögren’s Syndrome Is Associated with an Objective Decline in Physical Performance and Symptoms of Pain and Depression
Abstract Number: 1244

Clinical Characteristics and Outcomes in Patients with Primary Sjögren’s Syndrome-Associated Interstitial Lung Disease
Abstract Number: 1245

Smoking Might Reduce Odds of Sjӧgren’s Syndrome Among Rheumatoid Arthritis Patients
Abstract Number: 1246

Sjogren’s Syndrome and Its Risk of Cervical Lesions
Abstract Number: 1247

Features of Childhood Sjogren’s Syndrome: A Literature Review Based Cohort
Abstract Number: 1248

Patients Seropositive for La/SSB Without Ro/SSA Differ from Those Displaying La/SSB with Ro/SSA in a Single Center Sjogren’s Cohort
Abstract Number: 1249

The Impact of Anti-Ro Antibodies on the Pregnancy Outcome in Relation to Maternal Disease Presentation: A Descriptive Analysis of 231 Pregnancies
Abstract Number: 1250

Early Sjögren Antibodies: Potential Biomarker for Abnormal Minor Labial Salivary Gland Biopsy in Juvenile Sjögren’s Syndrome
Abstract Number: 1251

Assessing the Construct Validity of the Novel OMERACT Ultrasound Scoring System for Salivary Glands Target Lesions by Comparison with MRI in Patients with Sjögren’s Syndrome – An OMERACT Ultrasound Working Group Exercise
Abstract Number: 1252

Ultrasound-guided Parotid Gland Biopsy in Cadavers Performed by Rheumatologists – an OMERACT Ultrasound Working Group Study
Abstract Number: 1253

Re-evaluation of the Extent of Lymphocytic Infiltration May Improve the Diagnostic Accuracy of Lip Biopsy in Primary Sjögren’s Syndrome (pSS)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].